The post AUD/USD rises ahead of Australian CPI, USD weakness persists appeared on BitcoinEthereumNews.com. AUD/USD trades around 0.6930 on Monday at the time ofThe post AUD/USD rises ahead of Australian CPI, USD weakness persists appeared on BitcoinEthereumNews.com. AUD/USD trades around 0.6930 on Monday at the time of

AUD/USD rises ahead of Australian CPI, USD weakness persists

AUD/USD trades around 0.6930 on Monday at the time of writing, up 0.55% on the day, and maintains a positive tone at the start of the week. The pair is supported by a combination of domestic Australian factors and persistent pressure on the US Dollar (USD), amid political and monetary uncertainties in the United States (US).

The Australian Dollar (AUD) is mainly underpinned by anticipation surrounding the release of the Consumer Price Index (CPI) for the fourth quarter and December 2025, scheduled for Wednesday. Quarterly inflation is expected to have risen at an annual pace of 3.6%, compared with 3.2% previously, which would reinforce the view that inflationary pressures remain above the Reserve Bank of Australia’s (RBA) target. Hotter-than-expected CPI figures would strengthen expectations of a near-term interest rate increase. According to Reuters, markets currently assign around a 60% chance to a rate hike at the next RBA policy meeting, due next week.

Recent macroeconomic data in Australia also support this bias. Activity indicators, including Purchasing Managers Index (PMI) surveys, point to solid expansion in both manufacturing and services, while the labor market has shown a marked improvement, with strong job creation and a declining Unemployment Rate. These factors reinforce the perception that the economy is resilient enough to absorb further monetary tightening, even as RBA policymakers acknowledge that inflation has eased significantly from its 2022 peak.

At the same time, weakness in the US Dollar is lending additional support to AUD/USD. The Greenback is under pressure ahead of the expected announcement of the new Federal Reserve (Fed) Chair, an event investors view as potentially negative for the currency if future policy decisions are perceived as more aligned with the US administration’s economic agenda. Market participants are also focused on this week’s Fed policy decision, with consensus expectations pointing to interest rates being left unchanged in the 3.50%-3.75% range.

Against this backdrop, AUD/USD remains highly sensitive to upcoming Australian inflation data and shifts in global monetary policy expectations. A confirmation of firmer inflation pressures in Australia could extend support for the Australian Dollar, while any dovish surprise from the Reserve Bank of Australia or a renewed recovery in the US Dollar could temper the pair’s bullish momentum.

Australian Dollar Price Today

The table below shows the percentage change of Australian Dollar (AUD) against listed major currencies today. Australian Dollar was the strongest against the US Dollar.

USDEURGBPJPYCADAUDNZDCHF
USD-0.55%-0.48%-1.37%-0.01%-0.51%-0.64%-0.89%
EUR0.55%0.07%-0.80%0.53%0.04%-0.11%-0.35%
GBP0.48%-0.07%-0.88%0.46%-0.03%-0.18%-0.42%
JPY1.37%0.80%0.88%1.38%0.87%0.74%0.49%
CAD0.01%-0.53%-0.46%-1.38%-0.50%-0.63%-0.88%
AUD0.51%-0.04%0.03%-0.87%0.50%-0.14%-0.37%
NZD0.64%0.11%0.18%-0.74%0.63%0.14%-0.25%
CHF0.89%0.35%0.42%-0.49%0.88%0.37%0.25%

The heat map shows percentage changes of major currencies against each other. The base currency is picked from the left column, while the quote currency is picked from the top row. For example, if you pick the Australian Dollar from the left column and move along the horizontal line to the US Dollar, the percentage change displayed in the box will represent AUD (base)/USD (quote).

Source: https://www.fxstreet.com/news/aud-usd-advances-as-australian-cpi-looms-usd-under-pressure-202601261545

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26